Learn more about our policy experts.

Media Contacts

Angela Bradbery, Director of Communications
w. (202) 588-7741
c. (202) 503-6768
abradbery@citizen.org, Twitter

Don Owens, Deputy Director of Communications
w. (202) 588-7767

Karilyn Gower, Press Officer
w. (202) 588-7779

David Rosen, Press Officer, Regulatory Affairs
w. (202) 588-7742

Other Important Links

Press Release Database
Citizen Vox blog
Texas Vox blog
Consumer Law and Policy blog
Energy Vox blog
Eyes on Trade blog

Follow us on Twitter


Oct. 18, 2012

FDA Should Reject Dangerous Cholesterol Medication, Public Citizen Tells Advisory Committee

Mipomersen, Studied in an Unethical Clinical Trial, Shown to Cause a Plethora of Side Effects

WASHINGTON, D.C. – The U.S. Food and Drug Administration (FDA) should not approve the proposed cholesterol drug mipomersen because the study supporting approval was unethical and withheld an effective therapy from patients with a rare disease, Public Citizen said today in testimony to the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee.

Mipomersen is the first of a new class of drugs developed to treat homozygous familial hypercholesterolemia (HoFH), an extremely rare, fatal genetic condition that leads to very high blood cholesterol levels.

However, Public Citizen testified that the pivotal trial conducted in HoFH patients to support the drug’s approval was unethical because investigators withheld an effective, standard, life-prolonging treatment – LDL apheresis – from all patients.

This and other trials also showed that mipomersen caused liver damage, flu-like symptoms and possibly cancer in a large number of patients, according to FDA reviewers. Mostly due to these side effects, more than half of the HoFH patients stopped taking mipomersen before the trial was completed. But because the drug stays in the bloodstream long after discontinuation, side effects continued in many HoFH and other patients for several months afterwards.

Of further concern, animal studies also demonstrated that the drug is carcinogenic at doses close to those that would be used in human patients.

“In the zeal to demonstrate mipomersen to be effective, the trial excluded the use of a known beneficial treatment, LDL apheresis,” said Dr. Sidney Wolfe, director of Public Citizen’s Health Research Group. “It will be interesting to find out how the institutional review boards overseeing this trial (or the FDA) allowed it to go forward. Until a more ethical trial is conducted, with more encouraging safety results, the drug should certainly not be approved.”

To read today’s testimony, please visit http://www.citizen.org/hrg2079.


Copyright © 2016 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.

Public Citizen, Inc. and Public Citizen Foundation


You can support the fight for greater government and corporate accountability through a donation to either Public Citizen, Inc., or Public Citizen Foundation, Inc.

Public Citizen lobbies Congress and federal agencies to advance Public Citizen’s mission of advancing government and corporate accountability. When you make a contribution to Public Citizen, you become a member of Public Citizen, showing your support and entitling you to benefits such as Public Citizen News. Contributions to Public Citizen are not tax-deductible.

Public Citizen Foundation focuses on research, public education, and litigation in support of our mission. By law, the Foundation can engage in only very limited lobbying. Contributions to Public Citizen Foundation are tax-deductible.